Consumer Voice Releases Joint Statement on the Recent Johnson & Johnson Settlement

posted Jan 7, 2014, 11:05 AM by Dio Telmo

On Friday, November 8th, Consumer Voice, California Advocates for Nursing Home Reform, Center for Medicare Advocacy, Long Term Care Community Coalition and the Legal Aid Justice Center in Virginia released a joint statement on the recent Johnson & Johnson settlement, in which the company was ordered by the Department of Justice to pay $2.2 billion in civil and criminal fines for the illegal marketing of Risperdal. Risperdal, an antipsychotic medication approved for the treatment of schizophrenia, was marketed by Johnson & Johnson (J&J) for off-label use among elderly persons with dementia, despite the significant health risks that Risperdal and other antipsychotics pose to this population. The pharmaceutical company was also found responsible for paying kickbacks to physicians and pharmacies to encourage the sale of antipsychotic drugs such as Risperdal and Invega among individuals in long-term care. 

 
The joint statement on the J&J settlement, which can be read here, was prepared by Janet Wells, former Director of Public Policy at the Consumer Voice, and calls for improved national action to combat the misuse of antipsychotics like Risperdal among elderly persons with dementia. For additional information on the issue of antipsychotics being wrongly prescribed for the treatment of dementia, go to our website here.

Comments